Pharsight

1. Jylamvo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771701	SHORLA	Methotrexate formulation	Oct, 2034 (10 years from now)
US11129833	SHORLA	Methotrexate formulation	Oct, 2035 (11 years from now)

Market Authorisation Date: 29 November, 2022

Treatment: Treatment of adults with severe psoriasis with an oral solution of methotrexate

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
2MG/ML	SOLUTION;ORAL	Prescription

JYLAMVO family patents

2. Otrexup patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP19150366A	2022-09-04	Bandpay & Greuter	Granted and Under Opposition
EP06719329A	2019-10-07	Bandpay & Greuter	Patent maintained as amended
EP09719763A	2016-06-16	Ypsomed AG	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7744582	OTTER PHARMS	Needle assisted jet injector	Aug, 2019 (4 years ago)
USRE44846	OTTER PHARMS	Needle assisted jet injector	Aug, 2019 (4 years ago)
USRE44847	OTTER PHARMS	Needle assisted jet injector	Aug, 2019 (4 years ago)
US7776015	OTTER PHARMS	Needle assisted jet injector	Aug, 2019 (4 years ago)
US6746429	OTTER PHARMS	Needle assisted jet injector	Apr, 2020 (4 years ago)
US9629959	OTTER PHARMS	Prefilled syringe jet injector	Jan, 2026 (1 year, 8 months from now)
US8562564	OTTER PHARMS	Prefilled syringe jet injector	Jan, 2026 (1 year, 8 months from now)
US11446441	OTTER PHARMS	Prefilled syringe injector	Jan, 2026 (1 year, 8 months from now)
US9533102	OTTER PHARMS	Prefilled syringe jet injector	Jan, 2026 (1 year, 8 months from now)
US8021335	OTTER PHARMS	Prefilled syringe jet injector	Oct, 2026 (2 years from now)
US10709844	OTTER PHARMS	Injector safety device	Mar, 2029 (4 years from now)
US11684723	OTTER PHARMS	Injector safety device	Mar, 2029 (4 years from now)
US9867949	OTTER PHARMS	Injector safety device	Mar, 2029 (4 years from now)
US9421333	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (5 years from now)
US11497753	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (5 years from now)
US8579865	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (5 years from now)
US8945063	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (5 years from now)
US8480631	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (5 years from now)
US8814834	OTTER PHARMS	Injector safety device	May, 2031 (7 years from now)

Market Authorisation Date: 07 November, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
20MG/0.4ML (20MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
12.5MG/0.4ML (12.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
17.5MG/0.4ML (17.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.4ML (15MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
25MG/0.4ML (25MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
7.5MG/0.4ML (7.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued
22.5MG/0.4ML (22.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
10MG/0.4ML (10MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription

OTREXUP family patents

3. Rasuvo patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP07786239A	2012-10-29	Actavis Group ehf	Opposition rejected
EP07786239A	2011-09-15	Antares Pharma, Inc.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8664231	July, 2016	FWD Entered	MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH	Koios Pharmaceuticals LLC
US8664231	February, 2016	Terminated-Settled	MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH	Frontier Therapeutics, LLC
US8664231	July, 2014	Terminated-Settled	Medac Gesellschaft Fur Klinische	Antares Pharma, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231	MEDEXUS	Concentrated methotrexate solutions	Jun, 2029 (5 years from now)

Market Authorisation Date: 10 July, 2014